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ABSTRACT 
 
Background/Aims: PuraMatrix is a synthetic material consisting of 16-amino acid peptides 
that self-assemble into nanofibers, previously used as a scaffold for functional cell cultures. 
We conducted a clinical study to determine the safety and sealing properties of PuraMatrix in 
post-operative lymphorrhea following pelvic surgery in humans. Methodology: A total of 20 
patients who underwent rectal cancer resection were analyzed. The study group (n = 10) 
consisted of patients who received PuraMatrix, matched with a control group (n = 10) of 
patients operated on conventionally. Results: During the 2 to 3 month follow-up period, there 
were no abnormal findings or adverse events in any the patients who received PuraMatrix. 
We found that the patients who received PuraMatrix had significantly reduced post-operative 
drainage volumes compared with the patients in the control group. Conclusions: PuraMatrix 
is a safe and effective bio-compatible sealing material for the management of post-operative 
peritoneal effusion following pelvic surgery. 
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INTRODUCTION 
 
Post-operative lymphorrhea has been observed following lymphadenectomy during pelvic 
oncological surgery (1, 2). Rectal dissection results in exposure of the broad raw surface of 
the presacral space, and lymphatic and/or vascular channels transected during surgery can 
cause fluid to leak into the abdominal cavity (3). It is very difficult to effectively prevent 
lymphorrhea because a good field of view of the pelvic viscera is hard to obtain from an 
anatomical perspective. Peritoneal fluid accumulation is usually asymptomatic and eventually 
reabsorbed (4); however, it may cause complications including secondary infection, sepsis, 
chylous ascites, or thrombosis due to compression of blood vessels (5). In particular, ascites 
increases when associated with chronic liver disease, and frequently induces severe and 
life-threatening complications due to intestinal bacterial translocation (6). Although, 
previously, surgeons inserted a drain as a matter of routine, prophylactic drainage of the 
pelvis has been abandoned because of the risk of intra-abdominal infection as a route for 
ascending infection (7, 8). Therefore, there is currently need for peritoneal fluid accumulation 
to be reduced as much as possible following pelvic surgery.  
 PuraMatrix is a synthetic material consisting of 16-amino acid peptide fragments that 
self-assemble into a nano-fiber structure (9) (Fig. 1). It has been used as a synthetic 
extracellular matrix for cell culture. PuraMatrix also has rapid and potent hemostatic effects 
when applied during experimental surgery in rodents (10). When PuraMatrix comes into 
contact with blood and tissue fluids, the pH and salt concentrations cause nanofiber formation 
and gelation that blocks the blood vessels in the hemorrhagic area and generates a hemostatic 
effect without secondary effects upon the surrounding tissues. The safety and sealing efficacy 
of PuraMatrix may be superior to those of other topical hemostatic agents that are either 
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collagenous hemostatic materials produced from bovine collagen or fibrin glue produced 
from blood preparations, and a source of concern regarding possible viral infections. 
Moreover, topical hemostatic agents can cause secondary effects on the surrounding tissues 
during hemostasis such as compression, ablation, vascular contraction, coagulation, or 
adhesion due to cross-link formation (11, 12). 
 We hypothesize that post-operative peritoneal fluid accumulation can be reduced 
when PuraMatrix is used to stop bleeding during pelvic surgery. The aims of this study 
were to determine the safety and sealing effects of PuraMatrix as a bio-compatible sealing 
material for peritoneal effusion in patients undergoing rectal cancer surgery.  
 
METHODOLOGY 
 
Patients 
The patients were individuals that underwent rectal surgery at Okayama University 
Hospital, Okayama, Japan, and were enrolled between 2008 and 2009 in a study approved by 
the Ethical Committee of Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Okayama, Japan. Written informed consent was obtained from all 
patients before enrollment in the study. The selection criteria was for patients with rectal 
cancer who were at least 20 years old, were scheduled to undergo a surgical procedure, and 
had no previous history of use of hemostatic materials at the surgical site. Patients who 
underwent surgery for rectal cancer and did not receive any conventional hemostatic methods 
during the same period were selected as a control group.  
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PuraMatrix preparation 
The PuraMatrix hydrogel peptide is a synthetic peptide consisting of a 16-amino acid 
sequence (AcN-RADARADARADAR ADA-CNH2) and devoid of animal-derived materials 
and pathogens and, hence, risk of infection (9). PuraMatrix stock solution (Becton Dickinson 
Biosciences, Franklin Lakes, NJ) at a concentration of 10 mg peptide/ml was used in this 
clinical study.  
 
Surgical procedure 
During surgery for rectal cancer, after removing as much of the blood as possible, 2 
mL PuraMatrix per 5 cm2 was applied to the bleeding wound surface followed by another 
application of 2 mL PuraMartrix per 5 cm2. If hemostasis was not obtained, then the above 
procedure was repeated. After hemostasis was confirmed, excess PuraMatrix was carefully 
washed off with normal saline (Fig. 2). A closed drain was placed near the area where 
PuraMatrix was applied. The period of time between immediately after the surgery and 7:00 
AM on the following morning is defined as Day 1 after surgery. The drain was removed on 
Day 4 or when the drainage volume was less than 20 ml. Adverse events and systemic 
findings were monitored beginning one week before surgery and up to 14 days after surgery 
during the stay in the hospital. The patients were also followed-up every 4 to 6 months for 2 
years in outpatient care. 
 
Assessments 
The primary endpoint of the study was the sealing effects of PuraMatrix and the 
secondary endpoints were safety, amount of bleeding, and time required for hemostasis 
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during surgery. The sealing efficacy was assessed based on the post-operative drainage 
volume in a closed drain placed near the area where the hemostatic agent had been dispersed. 
The hemostatic effects were also evaluated for hemostatic status 5 minutes after the 
perioperative use of PuraMatrix.  
 
Blood chemistry 
Blood samples were obtained on pre-operative day 1 and on post-operative days 1, 4, 
7 and 14. Samples were analyzed for CRP (c-reactive protein), WBC (white blood cell), AST 
(aspartate transaminase), ALT (alanine transaminase), creatinine, and BUN (blood urea 
nitrogen) by standard laboratory methods.  
 
Statistical analysis 
Data were analyzed by Student’s t-test or Chi-Square test. p ≤ 0.05 was considered to 
be significant. 
 
RESULTS 
 
A total of 20 patients who underwent surgery for rectal cancer were evaluated in this study. 
Of these, 10 patients received PuraMatrix as a hemostatic agent during surgery. The other 10 
patients received no conventional hemostatic agents during the same period and were 
analyzed as a control group. The clinical characteristics of the patient population are shown 
in Table 1. In the group for which PuraMatrix was used, the age ranged from 46 years old to 
73 years old (average age: 65 years old) with 6 males and 2 females, and none of patients 
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enrolled in either the PuraMatrix or control groups had any previous history of surgery or use 
of hemostatic agents at the surgical site. There was no significant difference in age, stage of 
disease, or location of the cancer between patients who received PuraMatrix and the control 
group. 
During hospitalization, each patient’s general status was observed on a daily basis and 
blood tests were performed on Days 1, 4, and 7 after surgery. No significantly abnormal 
findings were observed in any of the PuraMatrix-treated patients with regard to CRP, WBC, 
AST, ALT, creatinine, or BUN (Fig. 3). No patients treated with PuraMatrix experienced 
significant discomfort and, within the follow-up period of 2 to 3 months after the surgery, 
there were no complications related to the use of PuraMatrix, suggesting the potential safety 
of PuraMatrix in human.  
In observations conducted 5 minutes after the perioperative use of PuraMatrix, it was 
confirmed that hemostasis was obtained without fail in all patients. No complications were 
observed with the perioperative hemostasis, and no postoperative hemorrhaging was 
observed in any of patients in the study. No significant difference was observed in surgery 
time, amount of bleeding during surgery, duration of hospitalization, or duration of drain 
insertion between the PuraMatrix and control groups (Table 2). 
The patients treated with PuraMatrix generated significantly less post-operative 
pelvic drainage fluid compared with patients in the control group (P < 0.01) (Fig. 4). The 
drained fluid from all patients including the control group was clear, not bloody. After the 
removal of the drain, the patients were found to have no accumulation of ascites either in the 
PuraMatrix-treated or control groups.  
Finally, in order to determine whether PuraMatrix has any homology with known 
human proteins, we searched a variety of gene databases. We found no homology with any 
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full-length or partial-length sequences (Table 3).  
 
DISCUSSION 
 
A serious concern during pelvic surgery for rectal cancer is damage to the sacral venus plexus, 
which can lead to massive bleeding. Therefore the selection of appropriate measures to stop 
bleeding are extremely important (13). Moreover, once bleeding occurs, there is an increased 
post-operative drainage volume even after appropriate hemostasis. Although peritoneal fluid 
accumulation is usually asymptomatic, there is a risk of complications such as infection of 
the ascitic fluid even in the absence of a contiguous source of infection or an intra-abdominal 
inflammatory focus (14). The present study investigated the potential application of synthetic 
peptide fragments that self-assemble into a nano-fiber structure as a bio-compatible sealing 
material to reduce the post-operative ascitic fluid accumulation after pelvic surgery in human.  
 PuraMatrix (acetyl-(argninyl-alanyl-aspartyl-alanine)4-amide; molecular weight: 
1,713) is a 16-residue, synthetic peptide solution consisting of a repeat sequence of 
arginine-alanine-aspartic acid-alanine and has no particular pharmacological activity (9). 
When the peptides of PuraMatrix come into contact with blood and tissue fluids, the pH and 
salt concentration of the fluids cause nanofiber self-assembly and gelation, which blocks the 
blood vessels in the hemorrhagic area and results in a hemostatic effect. The gelation of 
PuraMatrix is caused only by changes in pH and salt concentration and requires no 
interaction with biological molecules. PuraMatrix was originally developed as a functional 
culture medium, but has since been used in experimental animals for wound healing and bone 
regeneration. Additionally, the efficacy of PuraMatrix as a hemostatic agent has been 
demonstrated in experimentally-induced injury in rodents. The non-clinical efficacy of 
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PuraMatrix as a hemostatic material has been verified in rat cortex incision models, rabbit 
abdominal aortic perforation models, and rabbit liver partial resection models and was shown 
to be comparable to other hemostatic materials (absorbent local hemostatic materials using 
collagen) and hemostatic agents (fibrin glue) currently used in clinical settings. These 
findings led us to examine whether PuraMatrix could seal the disrupted lymphatic tissues and 
reduce the volume of post-operative peritoneal effusion when used for hemostasis in human.  
 We found that when hemostasis measures taken during surgery involving 
compression, suturing, or the like were ineffective or could not be performed, PuraMatrix 
stopped bleeding during in 10/10 cases. Moreover, there was no bloody drainage from the 
drain after surgery and there was significantly less drainage volume in the PuraMatrix group 
over the first few days after surgery. This suggests that PuraMatrix has a long-lasting sealing 
effect. Furthermore, none of the patients exhibited any obvious adverse events, and in the 
blood tests performed on Days 1, 4, and 7 after surgery none of the patients had any abnormal 
values believed to be caused by PuraMatrix. Thus, PuraMatrix is a safe and effective sealing 
material for preventing lymphorrhea after pelvic surgery.  
 Compared to other hemostatic or sealing materials, there are significant advantageous 
properties of PuraMatrix. Firstly, PuraMatrix is a clear material. It does not block the field of 
view, which is particularly important during endoscopic surgery making it is easy to 
determine whether the hemostatic effects have been achieved. In contrast, conventional 
hemostatic or sealing materials can block the surgical field, making application within a 
narrow field difficult (11, 12). Additionally, other agents might cloud the drainage fluid, 
whereas no such opacity of the drainage fluid was observed after the use of PuraMatrix. 
Secondly, PuraMatrix is applied as a solution and only gels when it comes into contact with 
body fluids, making it easy to apply. In many cases, conventional hemostasis is attempted 
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with ablation, clips, or solid hemostatic materials that are collagenous and are often difficult 
to apply during endoscopic surgery (13). In the current study, it was possible to readily apply 
PuraMatrix through an 8 Fr feeding tube inserted from a 5-mm trocar through the left lower 
abdomen and guided to the sacrum using a forceps during a laparoscopic high anterior 
resection. Good hemostasis and sealing was obtained without blocking the field of view. 
Thirdly, PuraMatrix is a synthetic product and is therefore free of infectious agents; in our 
study, there were no cases of surgical site infections. In contrast, existing hemostatic sealing 
materials that are in clinical use are produced from bovine collagen, or fibrin glue produced 
from blood preparations, leading to concerns regarding possible viral infections. Fourthly, 
PuriMatrix has no known homology with other signaling proteins.  
      In conclusion, the present study is the first report indicating the safety and sealing 
efficacy of PuraMatrix in humans. It is believed that not only will it be a significant case of 
the clinical application of nanotechnology in the field of surgery, but it will also eliminate the 
potential risk of infection caused by existing sealing agents that have been used for years, 
thus leading to improvements in safety for pelvic surgery for rectal cancer. 
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Figure Legends 
 
FIGURE 1. Structure and gelation of PuraMatrix. (A) PuraMatrix consists of a repeat 
sequence of arginine-alanine-aspartic acid-alanine. Under physiological pH and salt 
concentrations, PuraMatrix (B) self-assembles into sheets, (C) forms nanofibers, and then (D) 
gels. Thus, gelation of PuraMatrix is caused by contact with body fluids and consequent 
changes in pH and salt concentration; it requires no interaction with biological molecules. 
 
FIGURE 2. Application of PuraMatrix. (A) Proper compression was applied around the 
bleeding site and as much blood was removed as possible using normal saline and gauze, etc. 
(B) PuraMatrix (2 ml per 5 cm2) was applied to the bleeding surface, followed by another 
application of 2 ml per 5 cm2 PuraMatrix. If no hemostasis occurred, the above procedure 
was repeated. After an application, 2 to 3 minutes were allowed for hemostasis. c After 
hemostasis was confirmed, excess hemostatic material was washed away with normal saline. 
 
FIGURE 3. Blood test data for patients in which PuraMatrix was used (P1 to P10). Blood 
tests were conducted before surgery and on Days 1, 4, 7, and 14 after surgery for CRP, WBC, 
AST, ALT, creatinine, and BUN. Case 3 is a subject with multiple hepatic metastases who 
presented with a neoplastic inflammation reaction before surgery, and improvements relative 
to the preoperative levels were seen immediately after the surgery. None of the patients 
presented with AST or ALT levels exceeding 1.5 times the normal ranges observed at our 
hospital. Cases 4 and 7 are patients with chronic renal failure, but no deterioration was 
observed in creatinine or BUN levels after the surgery compared to the values before surgery. 
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FIGURE 4. The post-operative drainage volume of a closed drain placed near the area 
where the PuraMatrix had been dispersed was evaluated for sealing efficacy. The drainage 
fluid was collected and the total volume was measured. The drain was removed on Day 4 or 
when the drainage volume was less than 20 ml. * P < 0.01 




